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Abstract: Corticosteroids reduce insulin sensitivity in healthy individuals by 30- 62-percent. The aim of 
this research was to use model-based methods to determine whether this reduction is also true in critically 
ill patients and how it may affect tight glycaemic control. A clinically validated model-based measure of 
insulin sensitivity was used to quantify changes between two matched cohorts of 40 intensive care unit 
(ICU) patients from Christchurch hospital. A 9-percent reduction in median insulin sensitivity was seen 
between the control cohort and patients receiving corticosteroids (per patient dose equivalent to 160mg/d 
of hydrocortisone). On a per-patient basis 11- 22-percent reductions were observed with higher percentile 
patients having greater suppression of insulin sensitivity. This research has shown that corticosteroids 
cause a much lower reduction in insulin sensitivity for critically ill patients compared to healthy controls 
and may thus have far less impact than suspected on glycaemic control in the ICU setting. 
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1. INTRODUCTION 
It is known that corticosteroids increase insulin resistance in 
healthy individuals. However, there is a lack of data about 
whether this affect is also true for critically ill patients. 
Insulin resistance, defined by relatively low insulin-mediated 
glucose disposal, makes tight glycaemic control (TGC) of 
intensive care unit (ICU) patients more difficult. Treatment 
with corticosteroids may therefore make this task even 
harder. 
Several studies have reported decreases in the insulin 
sensitivity of healthy subjects of 30- 62-percent after short-
term administration of dexamethasone (2- or 6 mg/d) 
(Binnert et al. 2004, Larsson & Ahren 1996, Nicod et al. 
2003, Perry et al. 2003). Pagano et al. (1983) document a 
similar change with prednisone (15 mg/d). The mechanisms 
and pathways underlying these dramatic reductions in insulin 
sensitivity are not yet fully understood. Metabolic 
adaptations, including enhanced endogenous glucose 
production (EGP), increased plasma insulin concentrations, 
and reduced whole-body glucose disposal were also reported 
in the studies noted above.  
Hyperglycaemia is prevalent in critical care (Capes et al. 
2000, Chase et al. 2008, McCowen et al. 2001, Mizock 2001, 
Van den Berghe et al. 2001). Increased secretion of counter-
regulatory hormones stimulates endogenous glucose 
production and reduces effective insulin sensitivity 
(McCowen et al. 2001, Mizock 2001). Tight control of blood 
glucose has been shown to improve clinical outcomes, 
reducing the risk of severe infection (Bistrian 2001), 
myocardial infarction (Capes et al. 2000) and critical illnesses 
such as multiple organ failure and polyneuropathy (Van den 
Berghe et al. 2001). More importantly, van den Berghe et al 
(2006, 2001), Krinsley (2003) and Chase et al (2008) have 
shown that tight glucose control can reduce ICU mortality by 
18- 45-percent. 
Corticosteroids are used in critical care to treat a variety of 
inflammatory and allergic disorders.  
1.2 Hypothesis 
Insulin sensitivity is reduced by corticosteroids in critically ill 
patients, but potentially to a lesser extent than in healthy 
individuals. 
1.3 Aim 
The aim of this research was to use model-based methods to 
quantify the affect of corticosteroid therapy on the insulin 
sensitivity of ICU patients, to determine whether it is 
detrimental to TGC and patient outcome. 
2. SUBJECTS AND METHODS 
2.1 Subjects 
A clinically validated, model-based measure of insulin 
sensitivity (SI) was used to quantify changes in insulin 
sensitivity between two matched, critically ill cohorts. This 
research was conducted as a retrospective study using records 
from 80 patients admitted to the Christchurch ICU between 
2005 and 2007.  
A cohort of 40 patients who each spent 24 hours or more on 
the SPRINT protocol (Chase et al. 2008) and received 
corticosteroid therapy during this time was selected from the 
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available records. These patients were treated with one or 
more of; hydrocortisone, prednisone, prednisolone, methyl-
prednisolone or dexamethasone, with a median daily dose for 
the cohort equivalent to 160 mg of hydrocortisone (Derendorf 
et al. 1993, Melby 1977). These patients were also screened 
to avoid any use of beta-blockers, as they can affect glucose 
metabolism (Rizza et al. 1980). Where a patient did not 
receive steroid therapy for the entire time they were on 
SPRINT, their insulin sensitivity was considered to be 
affected by the drug for 12 hours following the last dose, to 
allow for the plasma concentration to recover.  
A matching control cohort that did not receive any 
corticosteroid or beta-blocker therapy was also selected from 
patients on the SPRINT protocol. Details of the two study 
cohorts are shown in Table 1. Importantly, glycaemic control 
was also matched to avoid any differences this might cause.  
The SPRINT protocol is a simple wheel-based system that 
modulates insulin and nutritional inputs, titrating doses to the 
patient-specific insulin sensitivity to provide tight glycaemic 
control (Chase et al. 2008). SPRINT has been used in the 
Christchurch ICU since August 2005 on more than 1000 
patients. The requirement for the patients in this study to be 
on the SPRINT protocol ensures that they have regular and 
accurate records of blood glucose levels, insulin administered 
and nutrition given. The use of these patient records falls 
under existing ethics approval granted by the Upper South 
Regional Ethics Committee, New Zealand. 
Table 1. Comparison of steroid and control cohorts. Where 
appropriate, data are shown as median [IQR†]. 
Control 
Cohort
Steroid 
Cohort
N 40 40
Mortality (%) 20 25 p = 0.59**
Operative/Non-operative 13/27 12/28 p = 0.8**
63.5 59.5
[45-73] [49-73]
19 21.5
[16-27] [18-26]
33.6 33.9
[22-53] [21-59]
129.5 116.5
[64-189] [90-186]
5.8 6.0
[5.4-6.2] [5.8-6.4]
0 160
[80-200]
Total time on Steroids 
(hrs) 0 4487
Total time on SPRINT 
(hrs) 7467 6022
AGE (yrs) p = 0.66*
Patient median blood 
glucose (mmol/l) p = 0.13
*
p = 0.60*APACHE II
p = 0.88*
Equivalent daily dose of 
hydrocortisone (mg)
p = 0.84*
APACHE II ROD (%)
Patient time on SPRINT 
(hrs)
 
†  [IQR] - Interquartile range 
*   p-values calculated with two-tailed Mann-Whitney U test. 
** p-values calculated with chi square test. 
2.2 Model-Based Insulin Sensitivity 
This study uses the clinically validated glucose-insulin model 
of Lin et al (2006). The model-based insulin sensitivity has 
been shown to correlate well with the insulin sensitivity 
index (ISI) determined by the euglycaemic clamp method 
(Lotz et al. 2006). The glucose-insulin system model is 
presented in equations (1)-(3), where SI is the insulin 
sensitivity. Blood glucose level is denoted G, while Q and I 
represent interstitial and plasma insulin concentrations 
respectively. The remaining rates and constants have been 
previously defined in literature (Lin et al. 2006, Lotz et al. 
2006). 
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Using this model and the patient data, an SI value is identified 
every hour for each patient while they are on the SPRINT 
protocol. If there is a gap in a patient record of longer than 5 
hours (for example, when a patient is in surgery), the 
identification of SI is suspended until the record resumes. In 
this way, 5844 and 7149 SI values were obtained for the 
steroid and control cohorts respectively. 
2.3 Analyses 
Lognormal statistics were used to provide an accurate 
description of the insulin sensitivity results, as typical 
distributions are asymmetric and skewed. For even 
moderately skewed distributions, the arithmetic mean is not a 
robust statistic, and will thus not match the defined central 
tendency expected. Lognormal statistics (median, 
multiplicative variance) are therefore a better, more robust 
metric. Baseline variables were compared using the two-
tailed Mann-Whitney U test or chi-square test. P–values of 
less than 0.05 were considered significant. 
Both by-cohort and per-patient analyses of the identified 
insulin sensitivities were undertaken. In both cases, the data 
was compared using cumulative distribution functions 
(CDFs). CDFs show the entire shape of the distribution, 
which is particularly useful when they are skewed. 
Examining the distribution of insulin sensitivities for each 
cohort provides information about the overall behaviour of a 
population. However, it is often also useful to look at the 
behaviour of per-patient or percentile patient results. For 
example, the theoretical median patient can shed light on 
how a typical patient from a population might behave even 
when it is difficult or impossible to actually identify a 
specific individual example. Similarly, more extreme 
percentile patients, such as at the 10th- or 90th-percentile can 
show how more extreme or variable patients might behave 
within this cohort.  
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Theoretical percentile patients are ‘created’ from the per-
patient CDFs of the cohort at several likelihood values. At 
each likelihood, the desired percentile value of insulin 
sensitivity is determined across all individual patients and 
this value forms part of the theoretical percentile patient’s 
CDF. An example is illustrated in Figure 1 at three likelihood 
values for the 50th-percentile patient.  
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Figure 1. Per-patient analysis - creating the theoretical 
median patient. 
Thus, the following comparisons of median SI are made: 
 Overall cohort. 
 On/off steroids. 
 First/last 24hrs (or half) of treatment. 
 25th, 50th and 75th percentile patients. 
 ∆SI over these patients 
3 RESULTS 
3.1 Overall cohort analysis 
The insulin sensitivities of patients receiving corticosteroids 
are only slightly lower than the control patients when the 
cohorts are compared. The median insulin sensitivity is 
reduced by 9-percent from 2.06x10-4- to 1.87x10-4 l/mU.min 
(p < 0.001).  
Within the steroid cohort, comparing the insulin sensitivities 
between the periods when the patients were receiving 
corticosteroids and the periods when they were not also 
shows a reduction in sensitivity. The median insulin 
sensitivity is reduced by 13-percent, from 2.16x10-4 
l/mU.min to 1.87x10-4 l/mU.min while receiving steroids (p < 
0.001). This latter result may be more a reflection of 
improvement in patient condition over time than a result of 
the steroid treatment. Just 172 of the 1535 hours (11%) of 
data during which patients in the steroid cohort were not 
receiving steroids were prior to treatment being commenced. 
The cumulative distribution functions for the insulin 
sensitivities of the cohorts are shown in Figure 2.  
Examining the insulin sensitivities for just the first and last 
24 hours (or half of stay if less than 48 hours) of patients 
receiving steroids shows a clear increase over the course of 
the treatment. The median insulin sensitivity increases by 32-
percent over time (p < 0.001). This improvement is mirrored, 
to a lesser extent, in the control cohort, where a 12-percent 
increase in the median is observed (p < 0.001). These results 
are shown in Figure 3 where the controls are higher valued, 
as in Figure 2. 
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Figure 2. CDFs of insulin sensitivities for the study cohorts. 
0 0.2 0.4 0.6 0.8 1 1.2
x 10-3
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Insulin Sensitivity SI (mmol/mU.min)
Li
ke
lih
o
o
d
CDFs showing change in insulin sensitivity during the course of treatment and stay
 
 
 
Figure 3. Evolution of insulin sensitivity during the course of 
treatment and stay for each cohort. 
3.2 Per-patient analysis 
A per-patient analysis of the data also shows a reduction in 
insulin sensitivity for those patients receiving corticosteroids. 
Figure 4 shows the cumulative distribution functions for the 
25th-, 50th- and 75th-percentile patients from both cohorts. 
There is a clear difference at all likelihood values.  
It can be seen that lower percentile patients have less of a 
difference than higher percentile patients. The 25th-percentile 
patient receiving corticosteroids has median insulin 
sensitivity reduced by 2.36x10-5 l/mU.min (15%) (p = 0.007) 
when compared with the 25th-percentile patient from the 
control cohort. The median and 75th-percentile patients have 
reductions of 3.99x10-5 l/mU.min (18%) (p = 0.002) and 
5.01x10-5 l/mU.min (18%) (p = 0.002), respectively.  
This trend can be seen more clearly in Figure 5, where the 
percent change in median insulin sensitivity is plotted against 
the patient percentile and a linear, least squares fit is shown. 
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(SI while on steroids) 
 
Steroid cohort  
(SI while off steroids) 
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Data for patients more extreme than the 10th- and 80th-
percentile is omitted, as the number of points making up the 
percentile patients is small and skewed by outlying values. 
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Figure 4. CDFs of insulin sensitivity for the 25th-, 50th- & 
75th-percentile patients from the study cohorts 
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Figure 5. Differences in insulin sensitivity across theoretical 
percentile patients. 
Figures 6 and 7 plot the distribution of insulin sensitivities for 
each of the 40 patients in the control and steroid cohorts. 
These plots clearly show that the outlying patients with 
higher insulin sensitivities tend to be highly variable and will 
therefore influence the more extreme theoretical percentile 
patients. 
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Figure 6. CDFs of insulin sensitivities for all control patients. 
The majority of patients however show a tight central 
tendency with a very narrow interquartile range at the 0.5 
likelihood (8.88x10-5 l/mU.min for the steroid cohort and 
1.16x10-4 l/mU.min for the control cohort). 
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Figure 7. CDFs of insulin sensitivities for all steroid patients. 
4 DISCUSSION 
Corticosteroids cause insulin resistance in healthy people. 
The aim of this research was to determine whether this 
change is also true of critically ill patients who are already 
significantly insulin resistant. The results indicate that there is 
reduction in insulin sensitivity in critically ill patients 
associated with the use of corticosteroids. However, this 
reduction is significantly less than that seen in healthy 
people. 
In this study, a 9-percent reduction in median insulin 
sensitivity was seen between patients receiving 
corticosteroids while on steroids and the control cohort. The 
dosage and particular drug received by patients varied 
between individuals and over the course of treatment. 
However, over the entire cohort, the median per-patient daily 
dose was equivalent to 160 [80-200] mg/d of hydrocortisone.  
In contrast, the 30- 62-percent reduction in insulin sensitivity 
reported in healthy subjects (Binnert et al. 2004, Nicod et al. 
2003, Pagano et al. 1983, Perry et al. 2003) was obtained 
with significantly lower steroid doses. Subjects in these 
studies were either administered with 2 mg/d of 
dexamethasone, equivalent to 50 mg/d of hydrocortisone 
(Binnert et al. 2004, Nicod et al. 2003, Perry et al. 2003) or 
15 mg/d of prednisone, equivalent to 60 mg/d of 
hydrocortisone (Pagano et al. 1983). Larsson and Ahren 
(1996) reported a 45-percent reduction with 6 mg/d 
dexamethasone (equivalent to 150 mg/d) hydrocortisone).  
Thus, healthy subjects received 62- 68-percent lower doses. 
The differences therefore cannot be attributed to dosing. 
Hence, there is a clear reduction in the suppression of SI in 
the critically ill. However, it is important to note that 
critically ill patients have SI values 8- 60-times lower than 
healthy subjects (Lin et al. 2006, Lotz et al. 2006). 
Within the steroid cohort, there is a 13-percent reduction in 
median insulin sensitivity between the periods during which 
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patients were receiving corticosteroids and the periods when 
they were not. However, this result is probably more a 
reflection of improvement in patient condition than the 
effects of steroids. In particular, only 172 hours of data was 
prior to treatment with corticosteroids, compared with 1363 
hours after treatment had ceased. Therefore, over 89-percent 
of insulin sensitivity values for the sub-cohort not receiving 
steroids came from the latter part of patients’ stays where 
improved condition would be expected in general.  
Figure 3 clearly shows that the insulin sensitivity values for 
patients increase over the course of their steroid treatment, so 
it seems that most, if not all, of the difference in insulin 
sensitivity within the steroid cohort can be attributed to 
improvement in patient condition over time, rather than the 
effects of corticosteroids. This increase over time matches 
clinical expectations (Chase et al. 2008). 
Comparing the insulin sensitivities on a per-patient basis 
confirms the results seen between cohorts. The reduction in 
median insulin sensitivity observed for theoretical percentile 
patients (11- 22-percent) is more than that seen over the 
cohort. However, it is still much less than seen in healthy 
people.  
Interestingly, looking between the 10th- and 80th-percentiles 
where the data is dense enough to provide a reliable 
distribution, there appears to be a linear relationship where 
the lower percentile patients have less of a reduction in 
insulin sensitivity and the higher percentile patients more. 
This trend indicates that patients with higher effective insulin 
sensitivities tend to get more suppression, while on 
corticosteroids. This relationship suggests that the 
mechanisms by which corticosteroids affect insulin 
sensitivity are saturable and may already be at or near 
saturation in critically ill patients, given their much lower SI 
compared with healthy individuals.  
Although much research has been conducted on the effects of 
corticosteroids on insulin sensitivity, very little is known 
about the mechanisms that cause them. Corticosteroids 
reduce insulin sensitivity directly, as well as disrupting 
glucose metabolism at the liver, pancreas and peripheral 
tissues.  
A number of studies have indicated that decreased cellular 
glucose uptake is at least partly responsible (Pagano et al. 
1983, Paquot et al. 1995, Tappy et al. 1994). However, it is 
unclear whether this result is due to reduced insulin binding 
at the receptor or disrupted glucose transport. Tappy et al 
(1994) showed that the decreased uptake cannot be attributed 
to reduced peripheral blood flow caused by the inhibition of 
insulin mediated vasodilatory action. Impaired intracellular 
glucose oxidation has also been shown to have a role in 
corticosteroid induced insulin resistance (Paquot et al. 1995, 
Tappy et al. 1994).  
Delaunay et al (1997) and Lambillotte et al (1997) show that 
corticosteroids suppress insulin secretion through a direct 
action on the pancreatic β-cells. However, the results from 
Binnert et al (2004), Besse et al (2005) and Nicod et al (2003) 
show a clear increase in glucose-induced insulin secretion 
after administration of dexamethasone. Perhaps there are 
competing pathways with the net affect depending upon 
specific physiological conditions.  
Endogenous glucose production is enhanced by 
corticosteroids. Increases of 28- 83-percent have been 
reported (Besse et al. 2005, Binnert et al. 2004, Nicod et al. 
2003, Pagano et al. 1983) Some of the variation is explained 
by the levels of suppression achieved by hyperinsulinaemia 
during the clamp procedure. Catecholamines also stimulate 
EGP (Barth et al. 2007, Rizza et al. 1980) and this may occur 
through a common mechanism. 
Corticosteroids are known to interact with the sympatho-
adrenal system, enhancing the synthesis and actions of 
catecholamines (Paquot et al. 1995, Taylor & Hancox 2000). 
The study by Paquot et al (1995) suggests that corticosteroids 
and sympathomimetic agents may impair glucose metabolism 
through common actions. Corticosteroids may therefore 
affect glucose metabolism and insulin sensitivity through a 
signalling pathway involving or intersecting with 
catecholamines and the sympathetic nervous system. 
The insulin sensitivity parameter in the model used for this 
research captures the relative net effect of altered EGP, 
endogenous insulin secretion (Uend), and peripheral and 
hepatic insulin mediated glucose uptake. Therefore, increased 
EGP, reduced insulin secretion or reduced insulin mediated 
glucose uptake result in a decrease in SI. Hence, 
corticosteroid mediated changes to glucose metabolism, in 
addition to the direct effect on insulin sensitivity, cause a 
relative reduction in the model-based SI. While taking into 
account net relative changes in these other metabolic 
parameters, the model-based SI still correlates very well (r = 
0.97) with clamp based insulin sensitivity, ISI (Lotz et al. 
2006), providing support for this overall analysis. 
Critically ill patients have elevated levels of circulating 
catecholamines and cortisol due to their stress response 
(Bessey & Lowe 1993, Mizock 2001). Any increase or 
enhancement of their action may have little effect due to 
saturation. The increased hepatic glucose production 
associated with corticosteroids may also be blunted as it is 
already significantly enhanced due to the patients’ condition.  
Healthy individuals, in contrast, typically have low levels of 
catecholamines and cortisol. They would therefore show 
much more significant reductions in SI and increases in EGP 
with the administration of corticosteroids. This difference 
could explain the limited suppression of SI in critically ill 
patients receiving corticosteroids seen in this research, 
compared with results reported for healthy subjects.  
5 CONCLUSIONS 
This research has shown that corticosteroids cause a much 
lower reduction in the insulin sensitivity of critically ill 
patients. A 9-percent reduction in median insulin sensitivity 
was seen between patients receiving corticosteroids and the 
control cohort. In addition, patients with higher effective 
insulin sensitivities tend to get more suppression. This result 
is in contrast to healthy individuals, where corticosteroids 
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result in a 30- 62-percent reduction in SI. These results 
suggest that the mechanisms and pathways by which 
corticosteroids affect insulin sensitivity and glucose 
metabolism are saturable and are already at or near saturation 
in critically ill patients. Use of corticosteroid treatment is 
therefore likely to have a much less significant impact on 
glycaemic control in the ICU setting than might be 
anticipated. However, this affect is also variable among 
patients, creating greater variability in the control problem. 
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